NCT02192359View on ClinicalTrials.gov

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 7, 2016

Primary Completion Date

February 21, 2022

Study Completion Date

October 15, 2025

Conditions
Recurrent Anaplastic AstrocytomaRecurrent Anaplastic OligoastrocytomaRecurrent Anaplastic OligodendrogliomaRecurrent GlioblastomaRecurrent GliosarcomaRecurrent Malignant GliomaRecurrent WHO Grade III Glioma
Interventions
BIOLOGICAL

Carboxylesterase-expressing Allogeneic Neural Stem Cells

Given intracranially

DRUG

Irinotecan

Given IV

DRUG

Irinotecan Hydrochloride

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER